Literature DB >> 17584096

Smoking, haemostatic factors, and cardiovascular risk.

Aurelio Leone1.   

Abstract

There is a strong relationship between cigarette smoking and haemostatic parameters to increase the risk of cardiovascular events. Smoking influences negatively coagulation-fibrinolysis cascade at any level, although it acts primarily on those pathways that are most important for an effective clot formation: endothelium, platelets, and fibrinogen. Endothelial dysfunction is a main consequence of smoke compounds with significant changes in initiating physiologic coagulation process; platelet adhesiveness and aggregation increases as a result of smoking; finally, fibrinogen/fibrin framework strengthens clot thickness. Therefore, the whole coagulation cascade activates the thrombi formation pathway under smoking action. The risk of thrombotic cardiovascular events increases its frequency with more severe atherosclerotic alterations if compared to similar events in nonsmokers. Changes in haemostatic factors produced by smoking appear to be related to female sex, especially for those women who use oral contraceptives. Thrombosis of coronary and cerebral arteries are found with a major incidence in young women who are users. In conclusion, cigarette smoking modifies haemostatic parameters via thrombosis with consequently more rate of cardiovascular events.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17584096     DOI: 10.2174/138161207780831347

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  17 in total

1.  Tobacco-smoking-related differential DNA methylation: 27K discovery and replication.

Authors:  Lutz P Breitling; Rongxi Yang; Bernhard Korn; Barbara Burwinkel; Hermann Brenner
Journal:  Am J Hum Genet       Date:  2011-03-31       Impact factor: 11.025

2.  Anatomical differences and network characteristics underlying smoking cue reactivity.

Authors:  Xiaochu Zhang; Betty Jo Salmeron; Thomas J Ross; Hong Gu; Xiujuan Geng; Yihong Yang; Elliot A Stein
Journal:  Neuroimage       Date:  2010-08-03       Impact factor: 6.556

Review 3.  Multicausality in fatty liver disease: is there a rationale to distinguish between alcoholic and non-alcoholic origin?

Authors:  Henry Völzke
Journal:  World J Gastroenterol       Date:  2012-07-21       Impact factor: 5.742

4.  Assessment of coronary heart disease risk by combined analysis of coagulation factors.

Authors:  Nena Aleksic; Yao-Wei W Wang; Chul Ahn; Harinder S Juneja; Aaron R Folsom; Kenneth K Wu
Journal:  Atherosclerosis       Date:  2008-03-14       Impact factor: 5.162

Review 5.  Target population for clinical trials on sarcopenia.

Authors:  M Cesari; M Pahor
Journal:  J Nutr Health Aging       Date:  2008 Aug-Sep       Impact factor: 4.075

6.  F2RL3 methylation in blood DNA is a strong predictor of mortality.

Authors:  Yan Zhang; Rongxi Yang; Barbara Burwinkel; Lutz P Breitling; Bernd Holleczek; Ben Schöttker; Hermann Brenner
Journal:  Int J Epidemiol       Date:  2014-02-07       Impact factor: 7.196

7.  Plasma concentrations of soluble CD40 ligand in smokers with acute myocardial infarction: a pilot study.

Authors:  Mehmet Kayrak; Ahmet Bacaksiz; Mehmet S Ulgen; Mehmet Akif Vatankulu; Kadriye Zengin; Selim S Ayhan; Mustafa Kemal Basaralı; Sadik Büyükbas; Aysel Kiyici
Journal:  Heart Vessels       Date:  2010-10-27       Impact factor: 2.037

8.  Tobacco and metabolic syndrome.

Authors:  Yatan Pal Singh Balhara
Journal:  Indian J Endocrinol Metab       Date:  2012-01

9.  Association between Fibrinogen and Carotid Atherosclerosis According to Smoking Status in a Korean Male Population.

Authors:  Hye Min Cho; Dae Ryong Kang; Hyeon Chang Kim; Sun Min Oh; Byeong-Keuk Kim; Il Suh
Journal:  Yonsei Med J       Date:  2015-07       Impact factor: 2.759

10.  Elevated resting heart rate, physical fitness and all-cause mortality: a 16-year follow-up in the Copenhagen Male Study.

Authors:  Magnus Thorsten Jensen; Poul Suadicani; Hans Ole Hein; Finn Gyntelberg
Journal:  Heart       Date:  2013-04-17       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.